Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience

被引：32

作者：

Le Bras, Fabien

Sebert, Marie

Kelaidi, Charikleia ^{[2
]}

Lamy, Thierry ^{[3
]}

Dreyfus, Francois ^{[4
,5
]}

Delaunay, Jacques ^{[6
]}

Banos, Anne ^{[7
]}

Blanc, Michel ^{[8
]}

Vey, Norbert ^{[9
]}

Schmidt, Aline ^{[10
]}

Visanica, Sorin ^{[11
]}

Eclache, Virginie ^{[12
,13
]}

Turlure, Pascal ^{[14
]}

Beyne-Rauzy, Odile ^{[15
]}

Guerci, Agnes ^{[16
]}

Delmer, Alain ^{[17
]}

de Botton, Stephane ^{[18
]}

Rea, Delphine ^{[19
]}

Fenaux, Pierre ^{[1
,13
,20
]}

Ades, Lionel ^{[1
,13
,20
]}

机构：

[1] Univ Paris 13, Hop Avicenne, AP HP, Serv Hematol Clin, F-93009 Bobigny, France

[2] G Papanikolaou Hosp, Dept Hematol & Bone Marrow Transplantat, Thessaloniki, Greece

[3] Hop Pontchaillou, Serv Hematol Clin, Rennes, France

[4] Hop Cochin, AP HP, Serv Hematol Clin, Paris, France

[5] Univ Paris 05, F-75270 Paris 06, France

[6] CHU Nantes, Serv Hematol, Nantes, France

[7] CH Cote Basque, Bayonne, France

[8] CH Chambery, Serv Hematol Chambery, Chambery, France

[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[10] CHRU Angers, Serv Malad Sang, Angers, France

[11] CH Metz, Serv Hematol Clin, Metz, France

[12] Hop Avicenne, AP HP, Serv Hematol Biol, Paris, France

[13] Univ Paris 13, F-93009 Bobigny, France

[14] Hop Dupuytren, Serv Hematol, Limoges, France

[15] Ctr Hosp Univ Toulouse, Serv Med Interne, Toulouse, France

[16] Hop Brabois Nancy, Serv Hematol, Vandoeuvre Les Nancy, France

[17] Hop Robert Debre, Serv Hematol Clin, Reims, France

[18] Inst Gustave Roussy, Serv Hematol, Villejuif, France

[19] Univ Paris 07, Hop St Louis, Paris, France

[20] INSERM, U848, Villejuif, France

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 11期

关键词：

Del 5q syndrome; Myelodysplasia; Lenalidomide; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA;

D O I：

10.1016/j.leukres.2011.05.034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% patients. Del 5q was isolated, with 1 additional and > 1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count > 150 G/L and platelet decrease by at least 50% during the first weeks of treatment (p = 0.001). Grade III-IV neutropenia and thrombocytopenia were seen in 74% and 37.9% of the cases, respectively, and 3 deaths were attributed to cytopenias. Eight (8%) patients developed deep venous thrombosis (DVT). Platelet decrease by less than 50% predicted a higher risk of DVT. Only 6 patients (6.3%) patients progressed to AML, but median follow-up time was short (18 months). We confirm the high rate of TI with Lenalidomide in lower risk MDS with del 5q. Very close patient monitoring for cytopenias and DVT is mandatory, especially during the first weeks of treatment. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1444 / 1448

页数：5

共 50 条

[1] Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era;: the GFM experience with EPO and thalidomide
Kelaidi, C.
Park, S.
Brechignac, S.
Mannone, L.
Vey, N.
Dombret, H.
Aljassem, L.
Starnatoullas, A.
Ades, L.
Giraudier, S.
de Botton, S.
Raynaud, S.
Lepelley, P.
Picard, F.
Leroux, G.
Daniel, M. T.
Bouscary, D.
Dreyfus, F.
Fenaux, P.
[J]. LEUKEMIA RESEARCH, 2008, 32 (07) : 1049 - 1053
[2] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Butrym, Aleksandra
Lech-Maranda, Ewa
Patkowska, Elzbieta
Kumiega, Beata
Bieniaszewska, Maria
Mital, Andrzej
Madry, Krzysztof
Torosian, Tigran
Wichary, Ryszard
Rybka, Justyna
Warzocha, Krzysztof
Mazur, Grzegorz
[J]. BMC CANCER, 2015, 15
[3] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Aleksandra Butrym
Ewa Lech-Maranda
Elżbieta Patkowska
Beata Kumiega
Maria Bieniaszewska
Andrzej Mital
Krzysztof Madry
Tigran Torosian
Ryszard Wichary
Justyna Rybka
Krzysztof Warzocha
Grzegorz Mazur
[J]. BMC Cancer, 15
[4] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
List, Alan
Dewald, Gordon
Bennett, John
Giagounidis, Aristotle
Raza, Azra
Feldman, Eric
Powell, Bayard
Greenberg, Peter
Thomas, Deborah
Stone, Richard
Reeder, Craig
Wride, Kenton
Patin, John
Schmidt, Michele
Zeldis, Jerome
Knight, Robert
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1456 - 1465
[5] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
Kelaidi, Charikleia
Park, Sophie
Brechignac, Sabine
Mannone, Lionel
Vey, Norbert
Dombret, Herve
Aljassem, Lina
Starnatoullas, Aspasia
Ades, Lionel
Giraudier, Setphane
de Botton, Stephane
Mahe, Beatrice
Lepelley, Pascale
Picard, Fracoise
Leroux, Genevieve
Daniel, Marie-Threrese
Bouscary, Didier
Dreyfus, Francois
Fenaux, Pierre
[J]. BLOOD, 2006, 108 (11) : 757A - 757A
[6] Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
Komrokji, Rami S.
Al Ali, Najla H.
Padron, Eric
Lancet, Jeffrey E.
List, Alan F.
[J]. BLOOD, 2011, 118 (21) : 1195 - 1195
[7] Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
Serin, Istemi
Eren, Rafet
Dogu, Mehmet Hilmi
[J]. JOURNAL OF HEMATOLOGY, 2020, 9 (1-2) : 33 - 36
[8] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
Gritsaev, S. V.
Martinkevitch, I. S.
Petrova, E. V.
[J]. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
[9] Efficacy of lenalidomide for treatment of anemia in secondary myelodysplastic syndrome (MDS) with chromosome 5q deletion
Mintzer, David Michael
Billet, Shira N.
[J]. BLOOD, 2007, 110 (11) : 226B - 226B
[10] 5q deletion myelodysplastic syndrome
Chari, Preethi S.
Chander, Smitha
Sundareshan, T. S.
Prasad, Sujay
[J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2017, 60 (02) : 301 - +

← 1 2 3 4 5 →